#USA #San Francisco #Nutex Health #Hagens Berman #Misstatements

Nutex Health Faces Serious Legal Troubles

Nutex Health, Inc. (NASDAQ: NUTX), a company that provides hospital and healthcare services, is currently embroiled in a class-action lawsuit alleging financial misconduct. The lawsuit, filed by Hagens Berman, claims that Nutex has engaged in fraudulent schemes in collaboration with a third-party billing firm. Allegations include inflating revenues and submitting improper claims to insurance companies, resulting in substantial financial losses for investors. This situation has been exacerbated by a recent critical report from Blue Orca Capital, which exposed the claims against Nutex and a partner billing firm, HaloMD.

According to the lawsuit, Nutex's coordinated scheme involved submitting a large number of ineligible claims and misrepresenting their legitimacy, which artificially inflated the company's revenue. The complaint underscores that these financial activities were the primary driver behind Nutex's reported earnings, yet were unsustainable and misleading. The fallout from these allegations has already taken a toll on Nutex's stock, which saw a dramatic decline following the publication of the Blue Orca report.

The Impact of Blue Orca’s Findings

The situation began to unfold with a report released on July 22, 2025, by short-seller Blue Orca Capital. This report claimed that HaloMD's successes were due to a systematic fraudulent scheme aimed at siphoning millions from insurance providers. Notably, HaloMD faced multiple lawsuits from organizations like Anthem and Blue Cross Blue Shield, accusing the firm of inundating arbitration systems with thousands of arbitrary claims. The report indicated that Nutex relied on these unsustainable reimbursement rates from the arbitration to prop up its stock prices. Following these revelations, shares of Nutex experienced a notable drop of over 10%.

Financial Reporting Mismanagement

In addition to the allegations about improper arbitration claims, the lawsuit also highlights that Nutex provided inaccurate financial reporting, misleading investors about its business practices. Specifically, it is alleged that Nutex overstated improvements in its financial controls, leading to misclassification of stock-based compensation as equity rather than liabilities. This accounting misjudgment came to light after Nutex's response to Blue Orca’s allegations was followed by a delay in the filing of its quarterly report.

Initially, Nutex claimed that it strongly disagreed with the allegations set forth by the short-seller and anticipated an upcoming update in the next quarterly report. However, on August 14, 2025, Nutex announced the postponement of its Form 10-Q filing, citing adjustments related to stock-based compensation obligations. This announcement led to a further plummet in share prices, with a significant 16.39% decline the day after the postponement.

Admissions and Revisions

The controversy at Nutex reached a watershed moment on August 21, 2025, when the company filed a Form 8-K. In this filing, the Audit Committee disclosed its conclusion that prior financial statements needed restating due to misjudgments in accounting for obligations related to the construction of new hospitals. Despite the reassessment of their processes, the lawsuit claims that this response did not effectively counter any of the allegations made by the Blue Orca report.

Seeking Justice for Investors

The class-action lawsuit aims to recover damages for investors who purchased Nutex securities during the alleged misconduct period. The allegations assert that Nutex's public statements were fundamentally misleading and have caused investors to incur significant financial losses as the truth about the company's operations came to light.

Hagens Berman is actively investigating these allegations, with partner Reed Kathrein stating their efforts focus on whether Nutex built its business model on questionable practices and whether its financial controls were sufficiently robust to safeguard investor interests.

If you have suffered losses as an investor in Nutex or possess relevant information that could assist in the investigation, Hagens Berman encourages you to come forward. They are also providing details about the SEC Whistleblower program for those with insider information. Their commitment to holding corporations accountable remains steadfast, as they continue to advocate for investors wronged by corporate negligence.

For additional information on the Nutex case and further updates, investors are encouraged to visit Hagens Berman’s website and follow their proceedings closely.